Roivant's ulcerative colitis drug from Pfizer shows promising data in early readout
Roivant’s ulcerative colitis drug acquired from Pfizer last month has already produced positive data in the first readout of the Phase IIb trial.
The company is now planning for a Phase III test, claiming in a press release that the drug has “best-in-indication potential” as a first- or second-line treatment. The trial included patients who had received prior therapy, including anti-TNF drugs, steroids, JAK inhibitors and other standard treatments, and some patients had a biomarker associated with the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.